Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   35504   clinical trials with a EudraCT protocol, of which   5838   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-002403-34
    Sponsor's Protocol Code Number:009175QM
    National Competent Authority:UK - MHRA
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2013-09-09
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedUK - MHRA
    A.2EudraCT number2013-002403-34
    A.3Full title of the trial
    A Randomized Phase II Study of Fulvestrant in Combination with the dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen Receptor-Positive Advanced or Metastatic Breast Cancer.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A randomized Phase II study comparing treatment combinatons of Fulvestrant and AZD2014, Fulvestrant and Everolimus or Fulvestrant alone for patients with advanced or metastatic breast cancer.
    A.3.2Name or abbreviated title of the trial where available
    MANTA
    A.4.1Sponsor's protocol code number009175QM
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorQueen Mary, University of London
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstraZeneca
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAZD2014
    D.3.2Product code AZD2014
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Afinitor
    D.2.1.1.2Name of the Marketing Authorisation holderNovartis Europharm Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEverolimus
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEverolimus
    D.3.9.1CAS number 159351-69-6
    D.3.9.4EV Substance CodeAS6
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Estrogen receptor-positive advanced or metastatic breast cancer
    E.1.1.1Medical condition in easily understood language
    Breast Cancer
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The main aims of this study are to: • Determine whether dual inhibition of mTORC 1 and mTORC2 with AZD2014 will increase the anti-tumour activity of endocrine treatment with fulvestrant in ER-positive advanced or metastatic breast cancer. • Determine whether inhibition of both mTORC 1 and mTORC2 using AZD2014 will have superior anti-tumour activity compared to inhibition of mTORC1 alone with everolimus, when combined with fulvestrant. • Explore whether additional efficacy is likely to be present in a subgroup with PI3K-pathway activation for whom it is hypothesised that there will be greater sensitivity to mTOR inhibitors • Characterize the patient population who might benefit from fulvestrant plus AZD2014 to identify potential predictors of sensitivity The primary objectives of this study are to: • Estimate the clinical benefit of fulvestrant + AZD2014 relative to fulvestrant + everolimus or fulvestrant alone, as measured by investigator-assessed progression-free survival (PF
    E.2.2Secondary objectives of the trial
    The secondary objectives of this study are to: • Estimate the clinical benefit of fulvestrant + AZD2014 relative to fulvestrant + everolimus or fulvestrant alone, as measured by PFS as assessed by an independent review facility [IRF] • Assess the clinical activity, as measured by response rate (RECIST 1.1), clinical benefit rate, duration of clinical benefit and duration of response, of fulvestrant + AZD2014 relative to fulvestrant + everolimus or fulvestrant alone • Establish the safety and tolerability of fulvestrant + AZD2014 relative to fulvestrant + everolimus or fulvestrant alone • Estimate the overall survival benefit of fulvestrant + AZD2014 relative to fulvestrant + everolimus or fulvestrant alone • Investigate the effects of fulvestrant +/- AZD2014 or everolimus on bone-turnover biomarkers • Compare the differences in patient reported outcomes as measured by the Functional Assessment of Cancer Therapy-General (FACT-G) scale together with the Breast-Anti-A and Endoc
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Written informed consent prior to admission to this study 2. Women, age ≥ 18 years 3. Histologically confirmed breast cancer 4. Metastatic or locally recurrent disease; locally recurrent disease must not be amenable to resection with curative intent (patients who are considered suitable for surgical or ablative techniques following potential down-staging with study treatment are not eligible). 5. Patients must have: a. at least one lesion, not previously irradiated, that can be measured accurately at baseline as ≥ 10mm in the longest diameter (except lymph nodes which must have short axis ≥ 15mm) with computed tomography (CT) or magnetic resonance imaging (MRI) which is suitable for accurate repeated measurements, or b. lytic or mixed (lytic + sclerotic) bone lesions in the absence of measurable disease as defined above; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible 6. Radiological or clinical evidence of recurrence or progression 7. ER-positive disease, defined as tumour cells being positive for ER with ≥1% of tumour cells positive for ER on IHC or IHC score (Allred) of ≥3 8. HER2-negative disease with 0, 1+ or 2+ intensity on IHC and no evidence of amplification on ISH. 9. Formalin fixed, paraffin embedded tumour sample from the primary and/or recurrent cancer must be available for central testing 10. Postmenopausal women. Women will be considered postmenopausal if they meet one of the following criteria: a. Age ≥50 years and 1 year or more of amenorrhea b. Age <50 years and 1 year or more of amenorrhea, with an estradiol assay <20pg/mL c. Age <50 with prior hysterectomy but intact ovaries with an estradiol assay <20pg/mL d. Status after bilateral oophorectomy (≥28 days prior to first study treatment) Note: Ovarian radiation or treatment with a luteinizing hormone-releasing hormone (LHRH) agonist (goserelin acetate or leuprolide acetate) is not permitted for induction of ovarian suppression. 11. Disease refractory to aromatase inhibitors (AI), defined as a. Disease recurrence while on, or within 12 months of end of adjuvant treatment with letrozole, anastrozole, or exemestane b. Progression while on, or within one month of end of letrozole, anastrozole or exemestane treatment for locally advanced or metastatic Breast Cancer. Note: Any number of lines of hormonal therapy before or after AI therapy is allowed. Note: Letrozole, anastrozole or exemestane do not have to be the last treatment prior to randomisation. 12. Haematologic and biochemical indices within the ranges shown below. These measurements must be performed within one week prior to randomisation a. ANC ≥ 1500 cells/µl, and platelet count ≥ 100000/µl b. Serum Creatinine <1.5 times ULN concurrent with creatinine clearance ≥50mL/min (measured or calculated by Cockcroft and Gault equation), confirmation of creatinine clearance is only required when creatinine is > 1.5 times ULN c. Bilirubin level < 1.5 x ULN if no demonstrable liver metastases or < 3 times ULN in the presence of liver metastases d. AST or ALT <2.5 x ULN e. International normalized ratio (INR) <1.5 and activated partial thromboplastin time (aPTT) <1.5 x ULN; for patients requiring therapeutic anticoagulation therapy, a stable INR ≤2.5 x ULN is required to mitigate potential bleeding f. No Clinically relevant and treatment resistant abnormalities in potassium, sodium, calcium (corrected for plasma albumin) or magnesium g. Fasting serum cholesterol ≤ 300 mg/dl or 7.75 mmol/L and fasting triglycerides ≤ 2.5 ×ULN. In case one or both of these thresholds are exceeded, the patient can only be included after initiation of statin therapy and when the above mentioned values have been achieved 13. ECOG performance status 0-2 14. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had a hysterectomy, bilateral oophorectomy, bilateral tubular ligation or is post-menopausal (total cessation of menses for ≥ 1 year; if the patient is of childbearing potential, she must have a negative serum pregnancy test within 2 weeks prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception (for example, intrauterine device [IUD], birth control pills unless clinically contraindicated, or barrier device) beginning 2 weeks before the first dose of investigational product and for 28 days after the final dose of investigational product.
    E.4Principal exclusion criteria
    1.Presence of life-threatening metastatic visceral disease, defined as extensive hepatic involvement or any degree of brain or leptomeningeal involvement (past or present), or symptomatic pulmonary lymphangitic spread. Patients with discrete pulmonary parenchymal metastases are eligible, provided their respiratory function is not compromised. 2.More than one line of prior chemotherapy for metastatic breast cancer 3.Prior chemotherapy, biological therapy, androgens, thalidomide, immunotherapy, other anticancer agents or any investigational agents within 14 days of starting study treatment (not including palliative radiotherapy at focal sites), radiotherapy with a wide field of radiation (greater than or equal to 30% marrow or whole pelvis or spine) within 4 weeks of starting study treatment, or strontium-90 (or other radiopharmaceuticals) within the past 3 months or major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access); with the exception of alopecia, all unresolved toxicities from prior treatment should be no greater than CTCAE grade 1 at the start of treatment 4.Prior treatment with fulvestrant or everolimus 5.Prior treatment with PI3K inhibitors, Akt inhibitors or other mTOR inhibitors. 6.Patients receiving concomitant immunosuppressive agents or chronic systemic corticosteroids (≥10mg prednisolone or an equivalent dose of other anti-inflammatory corticosteroids) use for ≥28 days at the time of study entry except in cases outlined below: Topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways diseases), eye drops or local injections (e.g. intra-articular) are allowed. Patients on stable low dose of corticosteroids for at least two weeks before randomisation are allowed 7.Current refractory nausea and vomiting, chronic gastrointestinal disease or inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of the study medication 8.Clinically significant pulmonary dysfunction 9.Significant cardiovascular disease; patients who have experienced any of the following procedures or conditions currently or in the preceding 12 months: a.Myocardial infarction, acute coronary syndromes (including unstable angina), or coronary angioplasty/stenting/bypass grafting. b.Symptomatic congestive heart failure (CHF) New York Heart Association (NYHA) Classes II-IV or LVEF <50% by either ECHO or MUGA c.Severe cardiac arrhythmia requiring medication or severe conduction abnormalities d.Poorly controlled hypertension (resting diastolic blood pressure >100 mmHg) e.Clinically significant valvular disease, cardiomegaly, ventricular hypertrophy, or cardiomyopathy 10.QTc prolongation defined as a QTc interval >470 msecs or other significant ECG abnormalities including 2nd degree (type II) or 3rd degree AV block or bradycardia (ventricular rate <50 beats/min) 11.Concomitant medications known to prolong QT interval, or with factors that increase the risk of QTc prolongation or risk of arrhythmic events (such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age) 12.Clinically significant abnormalities of glucose metabolism as defined by any of the following a.Diagnosis of diabetes mellitus type I (irrespective of management) or uncontrolled diabetes mellitus type II b.Glycosylated haemoglobin (HbA1C) ≥8.0% at screening (64 mmol/mol) (conversion equation for HbA1C [IFCC-HbA1C (mmol/mol) = [DCCT-HbA1C (%) – 2.15] x 10.929) 13.Exposure to potent or moderate inhibitors or inducers of CYP3A4/5 within 2 weeks before the first dose of study treatment (3 weeks for St John’s Wort and 5 weeks for phenobarbitone). 14.Exposure to potent or moderate inhibitors or inducers of CYP2C8 within 1 week before the first dose of study treatment. 15.Application of haemopoietic growth factors within 2 weeks before receiving study drug 16.Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator’s opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent. 17.History of hypersensitivity to active or inactive excipients of AZD2014 or everolimus or drugs with a similar chemical structure or class to AZD2014 or everlimus 18.History of hypersensitivity to active or inactive excipients of fulvestrant and/or castor oil. 19.Currently receiving (and are unwilling to discontinue) oestrogen replacement therapy (last dose ≤7 days prior to randomisation) 20.Psychological, familial, sociological or geographical conditions that do not permit compliance with the study protocol. 21.Detained persons or prisoners 22.Pregnant/nursing
    E.5 End points
    E.5.1Primary end point(s)
    The primary outcome measure for this study is progression-free survival.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Progression free survival is defined as the time from the date of randomisation to the date of first documented tumour progression based on investigator assessment (using RECIST 1.1) or death from any cause, whichever occurs first. Tumour assessments of progression will be performed at screening, weeks 8, 16 and 24, and every 12 weeks thereafter, at the end of treatment and at follow-up.
    E.5.2Secondary end point(s)
    The secondary outcome measures for this study are as follows: Efficacy 1. Progression-free survival, defined as the time from the date of randomisation to the date of first documented tumour progression as assessed by an independent review facility [IRF] (using RECIST 1.1) or death from any cause, whichever occurs first. 2. Objective response, defined as a complete or partial response, based on investigator and IRF assessment using RECIST 1.1. 3. Average change (%) in tumour size at 16 weeks compared to baseline, based on investigator and IRF assessment using RECIST 1.1; tumour size is defined as the sum of the longest diameters of the target (i.e. measurable tumour) lesions. 4. Clinical Benefit, defined as number of patients with complete or partial response or stable disease maintained ≥24 weeks, based on investigator and IRF assessment using RECIST 1.1). 5. Overall survival, defined as the time from date of randomisation to the date of death due to any cause. 6. Duration of response, defined as the time from first documentation of complete or partial response to disease progression based on investigator and IRF assessment using RECIST 1.1. 7. Duration of clinical benefit, defined as the time from randomisation to disease progression based on investigator and IRF assessment using RECIST 1.1 in patients with CB. 8. Percentage change in serum of serum beta C-terminal cross-linking telopeptide of Type I collagen (βCTx) and N-terminal propeptide of Type I procollagen (PINP) from screening/baseline to each time that samples are collected. 9. Patient reported outcomes, as assessed by the Functional Assessment of Cancer Therapy-General (FACT-G) scale together with the Breast-Anti-A and Endocrine Symptom (FACT-Band Anti-A-ES) subscales. Safety Outcome Measures The safety outcome measures for this study are as follows: • Incidence of serious adverse events • Incidence of grade 3 and 4 adverse events (CTCAE, version 4.03) • Incidence of all adverse events of all grades • Incidence of the following selected adverse events (any grade)  Hyperglycaemia  Diarrhoea  Stomatitis  Rash  Interstitial pneumonitis • Adverse events leading to discontinuation of the study medication • Changes in vital signs and clinical laboratory results during and following study drug administration Pharmacokinetics Outcome Measures The PK outcome measures for this study are as follows: • Plasma drug clearance (CL/F), estimated maximum drug concentration (Cmax), elimination half-life (t1/2) and volume of distribution (Vss/F) for AZD2014 • Cssmin for fulvestrant Exploratory Outcome Measures • Alterations in DNA and RNA, including mutational status, RNA expression levels, DNA copy number, and protein expression.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Efficacy1. Assessed at the end of the study by an independent review facility (IRF). 2. Assessed at the end of patient treatment (Investigator) and at the end of the study (IRF). 3. Assessed at week 16 and at the end of the trial. 4. Assessed at ≥24 weeks (investigator) and at the end of the study (IRF). 5. Assessed on patient death. 6&7. Assessed at disease progression (investigator) and at the end of the study (IRF). 8. Assessed at when the last patient has given their last sample for analysis. 9. Assessed when the last patient has submitted their last FACT questionnaire. Safety Assessed at all study visits and analysed at the end of the study. Pharmacokinetics Analysed when final patient submits last sample. Exploratory When final patients submits last sample.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned35
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA70
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    For the purposes of Clinical Trial Authorisation (CTA) under the European Union Directive 2001/20/EC, the study is deemed to have ended 30 days after the last patient receives the last dose of the investigational medicinal product (IMP). For all other purposes, the study end date is deemed to be the date of last data capture.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.1.1Number of subjects for this age range: 0
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.2.1Number of subjects for this age range: 0
    F.1.1.3Newborns (0-27 days) No
    F.1.1.3.1Number of subjects for this age range: 0
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.4.1Number of subjects for this age range: 0
    F.1.1.5Children (2-11years) No
    F.1.1.5.1Number of subjects for this age range: 0
    F.1.1.6Adolescents (12-17 years) No
    F.1.1.6.1Number of subjects for this age range: 0
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 0
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 0
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state120
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 240
    F.4.2.2In the whole clinical trial 240
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients will be treated until disease progression, treatment-limiting toxicity or death due to any cause, elective withdrawal, study completion or termination. Once the patients have completed this study, alternative treatments will be considered at the clinician's discretion. At the time of disease worsening, patients in the arm receiving ….
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-10-17
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-11-05
    P. End of Trial
    P.End of Trial StatusOngoing
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA